Literature DB >> 19148179

Prospects for improved bluetongue vaccines.

Polly Roy1, Mark Boyce, Robert Noad.   

Abstract

Bluetongue has been recognized as a viral disease of livestock for more than 100 years. Repeated incursions of Bluetongue into Europe since 1998 have been particularly devastating for highly sensitive European fine-wool sheep breeds, and have resulted in a resurgence of interest in vaccine manufacture. Fortunately, the virus and its serology are well understood and vaccination prevents the disease. However, current vaccines are not without their problems, and many new approaches are being tested to improve the safety and breadth of protection afforded. This review describes the leading technologies for improved bluetongue vaccines and looks ahead to how advances in other viral vaccines might be applied to this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148179     DOI: 10.1038/nrmicro2052

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  68 in total

1.  The use of baculovirus vectors for the production of membrane proteins in insect cells.

Authors:  R D Possee; C J Thomas; L A King
Journal:  Biochem Soc Trans       Date:  1999-12       Impact factor: 5.407

2.  Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep.

Authors:  M A Ramakrishnan; A B Pandey; K P Singh; R Singh; S Nandi; M L Mehrotra
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

3.  The control of bluetongue in an enzootic situation.

Authors:  B J Erasmus
Journal:  Aust Vet J       Date:  1975-04       Impact factor: 1.281

4.  An experimental inactivated vaccine against bluetongue.

Authors:  J Parker; K A Herniman; E P Gibbs; R F Sellers
Journal:  Vet Rec       Date:  1975-03-29       Impact factor: 2.695

5.  Immunologic response of sheep to inactivated and virulent bluetongue virus.

Authors:  J L Stott; T L Barber; B I Osburn
Journal:  Am J Vet Res       Date:  1985-05       Impact factor: 1.156

6.  Immunogenicity of bluetongue virus inactivated by gamma irradiation.

Authors:  C H Campbell
Journal:  Vaccine       Date:  1985-12       Impact factor: 3.641

7.  Molecular basis of bluetongue virus neutralization.

Authors:  J Kahlon; K Sugiyama; P Roy
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

Review 8.  Bluetongue virus assembly and morphogenesis.

Authors:  P Roy; R Noad
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

9.  Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains.

Authors:  Sushila Maan; Narender S Maan; Natalie Ross-smith; Carrie A Batten; Andrew E Shaw; Simon J Anthony; Alan R Samuel; Karin E Darpel; Eva Veronesi; Chris A L Oura; Karam P Singh; Kyriaki Nomikou; Abraham C Potgieter; Houssam Attoui; Eugene van Rooij; Piet van Rijn; Kris De Clercq; Frank Vandenbussche; Stéphan Zientara; Emmanuel Bréard; Corinne Sailleau; Martin Beer; Bernd Hoffman; Philip S Mellor; Peter P C Mertens
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

10.  Association of virulent and avirulent strains of bluetongue virus serotype 11 with premature births of late-term bovine fetuses.

Authors:  A S Waldvogel; G A Anderson; D L Phillips; B I Osburn
Journal:  J Comp Pathol       Date:  1992-05       Impact factor: 1.311

View more
  23 in total

1.  Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins.

Authors:  Xing Zhang; Mark Boyce; Bishnupriya Bhattacharya; Xiaokang Zhang; Stan Schein; Polly Roy; Z Hong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-23       Impact factor: 11.205

2.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

3.  In situ structures of RNA-dependent RNA polymerase inside bluetongue virus before and after uncoating.

Authors:  Yao He; Sakar Shivakoti; Ke Ding; Yanxiang Cui; Polly Roy; Z Hong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-26       Impact factor: 11.205

Review 4.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  RCDI/eRCDI: a web-server to estimate codon usage deoptimization.

Authors:  Pere Puigbò; Lluís Aragonès; Santiago Garcia-Vallvé
Journal:  BMC Res Notes       Date:  2010-03-31

6.  Reconstitution of authentic nanovirus from multiple cloned DNAs.

Authors:  Ioana Grigoras; Tatiana Timchenko; Lina Katul; Ana Grande-Pérez; Heinrich-Josef Vetten; Bruno Gronenborn
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

8.  Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Authors:  Jenna Anderson; Sara Hägglund; Emmanuel Bréard; Loic Comtet; Karin Lövgren Bengtsson; John Pringle; Stéphan Zientara; Jean Francois Valarcher
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

9.  Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formation.

Authors:  Eiko Matsuo; Polly Roy
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.